TNF and chronic kidney disease: Similarly, clinical trials conducted in CKD patients with stage 3 or higher reported a stabilization of renal function and decreased circulating levels of TNFα, fibrinogen, and CRP after PTX treatment [202], and reductions in proteinuria and urinary levels of TNFα and MCP1 after 1 year with add-on PTX to ARB background therapy [203].